The Calmer CO secures $2m pa Supply Agreement
Released
Released
Announcement PDF
The Calmer Co International Limited
96 Victoria Street West End Queensland 4101
ACN: 169 441 874
Doc 1410973978.3
26 February 2026 ASX RELEASE
The Calmer Co. Secures $2m per Annum
Minimum Revenue via Strategic CO2 Kava
Supply Agreement
Brisbane, Australia – The Calmer Co. International Limited (ASX: CCO), a leading consumer
packaged goods company specialising in kava and other natural products that promote
relaxation, sleep support, and healthier alternatives to alcohol, is pleased to announce that
it has entered into a material Master Supply Agreement with a leading U.S.-based kava
functional beverage company, covering the supply of premium CO₂-extracted kava
ingredients.
The agreement is expected to deliver approximately $2 million in revenue per annum,
subject to a minimum commitment of AU$1,581,884 over 24 months, production scheduling,
delivery timing and foreign exchange movements.
Commercial Highlights
• Material 24-month supply agreement for high-specification CO₂ kava
extract
• Minimum contracted revenue of approximately of AU$1,581,884 over the
24 months (Commitment), but it is anticipated, based on the quarterly
product inventory requested by the customer, that demand will likely
equate to revenue of approximately $2 million per annum during the term
• Quarterly supply framework aligned to customer production planning
• USD-denominated pricing with defined review mechanisms linked to raw
material movements
• Non-exclusive arrangement, preserving the Company’s ability to supply
other global customers
• Engage directly with us on Investor Hub via this link.
Doc 1410973978.3 2
Founder and CEO, Zane Yoshida, commented:
“This agreement represents a significant milestone in the execution of our B2B ingredients
strategy. Securing minimum contracted revenue provides strong revenue visibility and validates
our investment in vertically integrated sourcing and advanced CO₂ extraction capability.
The structure of the agreement allows both parties to scale volumes over time as demand for
kava-based functional beverages continues to expand in the U.S. market.”
Details of Agreement
The term of the agreement is 24 months.
While the contract does not require that the customer purchase a minimum quantity of
products quarterly, the Company has agreed to maintain a minimum stipulated quarterly
inventory of the products at the request of the customer.
The Customer must purchase any shortfall in the Commitment by the end of the 24 month
term, if not already purchased.
The contract other contains typical commercial supply terms, including mutual warranties,
insurance requirements, deposits on placement of orders, payment terms and sale price
adjustment based on the purity of kavalactone delivered by the Company, and may be
terminated on 30 days' notice for an unremedied breach.
Strategic Rationale
The agreement further positions The Calmer Co. as a preferred supplier of premium kava
ingredients to international beverage and wellness brands, supporting the Company’s
strategy to expand higher-margin B2B revenues and diversify beyond consumer packaged
goods.
Outlook
The Company expects the agreement to contribute materially to B2B revenue growth.
Revenue recognition will depend on purchase order timing, production schedules and
delivery under the agreement.
ASX Compliance Disclosure
Pursuant to ASX Compliance Update 02/25:
Doc 1410973978.3 3
• it does not consider the identity of the counterparty to the agreement to be
information that a reasonable person would expect to have a material effect on the
price or value of the Company's securities;
• confirms that this announcement contains all material information relevant to
assessing the impact of the contract on the price or value of the Company's securities,
and is not misleading by omission; and
• includes a description of the counterparty that is sufficient to describe any market
sensitive information about the counterparty, including its standing and
creditworthiness.
This announcement has been approved by the Board of Directors.
ends
For further information
Investor & Media Relations
Zane Yoshida
investors@thecalmerco.com
About The Calmer Co.
The Calmer Co. International Limited (ASX:CCO) is a fast growing beverage business
leveraging a global opportunity in kava and other natural products that replace alcohol and
support relaxation and sleep.
Our products are delivered to consumers globally through e-commerce channels and blue-
chip retail distribution partners, supported by a reliable farm to shelf supply chain.
The product range includes drinking powders, natural and flavoured kava shots,
concentrates and capsules, sold under the brands Fiji Kava®
, Taki Mai®
and Danodan
Hempworks in markets including USA, Australia, New Zealand, China and the Pacific
Islands.
Forward looking statements
This ASX release includes certain forward-looking statements that are based on
information and assumptions known to date and are subject to various risks and
1. "tmall.com Competitive Analysis, Marketing Mix and Traffic - Alexa". www.alexa.com.
Doc 1410973978.3
4
uncertainties. Actual results, performance or achievements could be significantly different
from those expressed in, or implied by, these forward-looking statements. Such forward-
looking statements are not guarantees of future performance and involve known and
unknown risks, uncertainties and other factors, many of which are beyond the control of
the Company. These factors may cause actual results to differ materially from those
expressed in the statements contained in this announcement.
Share your feedback
Discover